Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.51 |
| ▸ | BMP1 | P13497 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578425 | 0.92 | PTGES (0.53) | TAS2R14PTGESTAS2R8CXCR3KEAP1 | |
| SCHEMBL5928397 | 0.92 | PTGES (0.53) | TAS2R14PTGESTAS2R8CXCR3KEAP1 | |
| SCHEMBL7959979 | 0.91 | RORC (0.44) | TAS2R14BACE1 | |
| SCHEMBL7959974 | 0.91 | RORC (0.44) | TAS2R14BACE1 | |
| SCHEMBL2576474 | 0.91 | RORC (0.44) | TAS2R14BACE1 | |
| SCHEMBL2582931 | 0.89 | TAS2R14 (0.47) | TAS2R14 | |
| SCHEMBL2578910 | 0.89 | TAS2R14 (0.47) | TAS2R14CXCR3BACE1 | |
| SCHEMBL7256999 | 0.87 | TAS2R14 (0.53) | TAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL6714647 | 0.87 | TAS2R14 (0.53) | TAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL2578860 | 0.86 | MAPK1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | claimed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | claimed |
| US-6455581-B1 | INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | claimed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | claimed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | claimed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | TAS2R14 4157/4885PTGES 2316/4885TAS2R8 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.